Conduit Pharmaceuticals Inc.

CDT Expands Multi-Pathway Value Creation Strategy Across Pharma, IP and AI-Driven Discovery

CDT Equity Expands Tapinarof Intellectual Property Portfolio with Two New Patent Filings

CDT Identifies Rare Disease Opportunities Through Sarborg Signature Analysis, Advancing Out-Licensing Strategy

CDT Equity Stockholders Approve All Proposals at Special Meeting, Positioning the Company for Next Phase of Growth

CDT Equity Notes Sarborg Filing of U.S. Provisional Patent Application for AI Signature Agent